"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 31 | 31 |
| 2004 | 0 | 61 | 61 |
| 2005 | 1 | 63 | 64 |
| 2006 | 0 | 66 | 66 |
| 2007 | 0 | 89 | 89 |
| 2008 | 0 | 77 | 77 |
| 2009 | 1 | 94 | 95 |
| 2010 | 1 | 104 | 105 |
| 2011 | 0 | 87 | 87 |
| 2012 | 1 | 110 | 111 |
| 2013 | 0 | 110 | 110 |
| 2014 | 0 | 128 | 128 |
| 2015 | 0 | 116 | 116 |
| 2016 | 0 | 108 | 108 |
| 2017 | 0 | 94 | 94 |
| 2018 | 0 | 87 | 87 |
| 2019 | 1 | 86 | 87 |
| 2020 | 0 | 65 | 65 |
| 2021 | 0 | 69 | 69 |
| 2022 | 0 | 20 | 20 |
| 2023 | 0 | 27 | 27 |
| 2024 | 0 | 60 | 60 |
| 2025 | 0 | 14 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
-
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
-
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers. Neoplasia. 2025 May; 63:101157.
-
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194.
-
Dynamic investigation of hypoxia-induced L-lactylation. Proc Natl Acad Sci U S A. 2025 Mar 11; 122(10):e2404899122.
-
Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy. ACS Nano. 2025 03 11; 19(9):8852-8866.
-
Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy. EMBO Mol Med. 2025 Apr; 17(4):645-678.
-
Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance. J Vis Exp. 2025 Feb 14; (216).
-
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC). J Med Chem. 2025 Feb 27; 68(4):4961-4987.
-
Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy. Clin Cancer Res. 2025 Feb 03; 31(3):588-602.